Change of dosing paradigm in oncology

[1] Pinkel D. The use of body surface Area as a Criterion for Drug Dosage in Cancer Chemotherapy. Cancer Research. 1958 Aug;18(7):853–856. PinkelD The use of body surface Area as a Criterion for Drug Dosage in Cancer Chemotherapy Cancer Research 1958 Aug 18 7 853 856 Search in Google Scholar

[2] Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer. 2012 Sep 25;107(7):1100–6. ChatelutE White-KoningML MathijssenRH PuissetF BakerSD SparreboomA Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents Br J Cancer 2012 Sep 25 107 7 1100 6 Search in Google Scholar

[3] Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991 Mar;9(3):491–8. AbbruzzeseJL GrunewaldR WeeksEA GravelD AdamsT NowakB A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 1991 Mar 9 3 491 8 Search in Google Scholar

[4] Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, et al. TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicenter, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017 Jul;18(7):929–945. CameronD MordenJP CanneyP VelikovaG ColemanR BartlettJ TACT2 Investigators Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicenter, phase 3, open-label, randomised, controlled trial Lancet Oncol 2017 Jul 18 7 929 945 Search in Google Scholar

[5] Coombes RC, Kilburn LS, Tubiana-Mathieu N, Olmos T, Van Bochove A, Perez-Lopez FR, et al. Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. Eur J Cancer. 2016 Jun;60:146–53. CoombesRC KilburnLS Tubiana-MathieuN OlmosT Van BochoveA Perez-LopezFR Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer Eur J Cancer 2016 Jun 60 146 53 Search in Google Scholar

[6] Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, et al. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). Lung Cancer. 2019 Jan;127:103–111. HalmosB TanEH SooRA CadranelJ LeeMK FoucherP Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo) Lung Cancer 2019 Jan 127 103 111 Search in Google Scholar

[7] Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 2016 Nov;27(11):2103–2110. YangJC SequistLV ZhouC SchulerM GeaterSL MokT Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials Ann Oncol 2016 Nov 27 11 2103 2110 Search in Google Scholar

[8] Nakashima M, Ide K, Kawakami K. Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study. Target Oncol. 2019 Jun;14(3):295–306. NakashimaM IdeK KawakamiK Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study Target Oncol 2019 Jun 14 3 295 306 Search in Google Scholar

[9] Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 Sep 24;383(13):1207–1217. HongDS FakihMG StricklerJH DesaiJ DurmGA ShapiroGI KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors N Engl J Med 2020 Sep 24 383 13 1207 1217 Search in Google Scholar

[10] US Food and Drug Administration: FDA approves first targeted therapy for lung cancer mutation previously considered resistant to drug therapy. 2021 May 28 US Food and Drug Administration FDA approves first targeted therapy for lung cancer mutation previously considered resistant to drug therapy 2021 May 28 Search in Google Scholar